Neurological symptom burden at diagnosis affects survival
Brain metastases occur in approximately 35 % of patients with metastatic NSCLC and are associated with a variety of neurological symptoms, as well as poor prognosis . However, little is known about the prognostic impact of the symptomatic burden of CNS lesions at the time of diagnosis. This was assessed by an analysis based on a real-life cohort of 1,608 NSCLC patients from the Vienna Brain Metastasis Registry with newly diagnosed brain metastases . Neurological symptoms were evident in 73.8 %. Symptoms included neurological deficits (61.3 %), signs of increased intracranial pressure (30.3 %), epileptic seizures (13.6 %), and neuropsychological symptoms (14.5 %).
According to this analysis, oligosymptomatic or asymptomatic patients, compared to symptomatic patients, experienced significantly longer median OS after their diagnosis of brain metastases (11 vs. 7 months; p < 0.001). Interestingly, signs of increased intracranial pressure showed a significant correlation with prolonged survival (8 vs. 6 months in patients without increased intracranial pressure; p = 0.032). A multivariate analysis identified an independent association between the presence of neurological symptoms and survival from the time of diagnosis. Overall, this study highlights the importance of integrating the neurological symptom burden into the prognostic assessment of patients with NSCLC and brain metastases.
Outcomes according to CNS disease: single-agent pembrolizumab…
The KEYNOTE-001, 010, 024, and 042 trials compared pembrolizumab monotherapy with chemotherapy in NSCLC patients [3-6]. A pooled analysis of these four studies was performed to investigate the effects of pembrolizumab in PD-L1–positive disease according to the presence of brain metastases at baseline . Exploratory subgroup analyses for patients with CNS lesions had been prespecified in all trials. Mansfield et al. presented data for a total of 3,170 individuals 293 of whom had brain metastases (199 and 94 of these received pembrolizumab and chemotherapy, respectively), while 2,877 showed no cerebral disease (pembrolizumab: n = 1,754; chemotherapy: n = 1,123). Approximately half of the patients in each treatment group had a tumor proportion score (TPS) ≥ 50 %.
The clinical benefit of pembrolizumab in patients with TPS ≥ 50 % was similar irrespective of the presence of brain metastases at baseline. Median OS was 19.7 vs. 9.7 months for the pembrolizumab and chemotherapy arms in patients with CNS lesions (HR, 0.78), and 19.4 vs. 11.7 months in those without (HR, 0.66). Comparable risk reductions resulted for PFS, with 4.1 vs. 4.6 months in patients with brain metastases (HR, 0.70) and 6.5 vs. 6.1 months in those without (HR, 0.69). Likewise, in the group with TPS ≥ 1 %, pembrolizumab gave rise to similar OS and PFS effects.
Response rates measured at all tumor sites were higher with pembrolizumab than with chemotherapy for patients with and without brain metastases. In the group with cerebral lesions, median duration of response had not been reached yet for pembrolizumab-treated patients with both TPS ≥ 50 % and TPS ≥ 1 %, while it was 7.6 and 8.3 months, respectively, with chemotherapy. Pembrolizumab monotherapy showed a manageable safety profile irrespective of the presence of brain metastases. In their conclusion, the authors emphasized that prembrolizumab monotherapy is a standard-of-care therapy for patients with PD-L1–positive advanced NSCLC including those with treated, stable brain metastases.
… and pembrolizumab plus chemotherapy
In similar vein, Powell et al. reported an exploratory pooled analysis of the KEYNOTE-021, 189, and 407 trials that evaluated the outcomes in NSCLC patients with and without stable brain metastases at baseline . These studies had tested first-line pembrolizumab plus platinum-based chemotherapy compared to chemotherapy [9-12]. Among a total of 1,298 patients, 171 had brain metastases at the time of study inclusion (pembrolizumab plus chemotherapy: n = 105; chemotherapy: n = 66) and 1,127 did not (pembrolizumab plus chemotherapy: n = 643; chemotherapy: n = 484).
Pembrolizumab plus chemotherapy improved outcomes over chemotherapy alone in both groups (Table 1). This was true for OS, PFS, ORR, and duration of response. The combination had a manageable safety profile in patients with and without brain metastases. In the experimental arm, the presence of cerebral lesions was not associated with an increased rate of adverse events affecting the CNS. The authors noted that pembrolizumab plus chemotherapy is a standard-of-care strategy for patients with advanced NSCLC including those with treated and untreated asymptomatic brain metastases.
GIDEON: real-world experience with afatinib
In patients with EGFR mutations, the proportion of NSCLC patients who develop brain metastases is as high as 40 % to 60 % [13-15]. A subanalysis of the non-interventional German GIDEON study that prospectively assessed the real-world use of afatinib in the setting of EGFR-mutant advanced NSCLC demonstrated activity of this treatment in patients with baseline brain metastases . GIDEON included 49 patients with cerebral lesions (32.5% of the total population). Notably, this proportion is higher than in the randomized controlled trials conducted with afatinib [17, 18].
The presence or absence of brain metastases had no influence on ORR or DCR (Table 2). In line with the negative prognostic impact of CNS lesions, median PFS was shorter in patients with brain metastases than in those without (10.6 vs. 16.0 months). Median OS had not been reached yet at the time of the analysis. The safety results were consistent with those reported in the pivotal LUX-Lung clinical trials [18-20], and adverse events occurring during afatinib treatment did not differ across patients with and without brain metastases. Taken together, these data underline the efficacy and safety of afatinib in patients with CNS lesions, thus supporting the use of afatinib in this treatment setting.